ProfileGDS5678 / 1434079_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 75% 76% 75% 75% 72% 75% 70% 75% 75% 75% 73% 76% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1859377
GSM967853U87-EV human glioblastoma xenograft - Control 25.029975
GSM967854U87-EV human glioblastoma xenograft - Control 35.0672976
GSM967855U87-EV human glioblastoma xenograft - Control 45.0189975
GSM967856U87-EV human glioblastoma xenograft - Control 54.9269975
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5161772
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.830375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3984370
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9285275
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9488575
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9379275
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.773873
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0178276
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9415975